Moyamoya Disease: Recognition, Suzuki Staging, and the Revascularization Decision
Recurrent anterior-circulation strokes in a young patient, distal carotids narrowing on both sides, and a haze of tiny collaterals — the angiographic "puff of smoke." Medical therapy alone doesn't fix hemodynamic failure; recognizing moyamoya early is what buys the revascularization option.
Moyamoya is a hemodynamic disease — the treatment that changes its course is flow, not a pill.
- →Moyamoya is progressive stenosis of the distal internal carotid arteries and proximal circle of Willis, with fragile basal collaterals that make the angiographic "puff of smoke." Disease = idiopathic and typically bilateral; syndrome = the same vasculopathy with a company it keeps (sickle cell, NF1, Down syndrome, prior skull irradiation).
- →Presentation is bimodal: children with ischemia — classically provoked by crying or hyperventilation — and adults with ischemia or hemorrhage from rupture of the overworked collaterals.
- →Think of it when strokes or TIAs recur in the same anterior-circulation borderzones of a young patient, when both distal ICAs look narrow on CTA/MRA, or when FLAIR shows the leptomeningeal "ivy sign." Catheter angiography stages it (Suzuki I–VI).
- →Surgical revascularization — direct STA-MCA bypass, indirect synangiosis, or both — is the treatment for symptomatic or hemodynamically compromised disease; the JAM trial showed direct bypass reduced rebleeding in adult hemorrhagic moyamoya.
- →Everyday care is hemodynamic protection: avoid hypotension, dehydration, and hyperventilation (including in anesthesia and even in crying children), usually a single antiplatelet for ischemic phenotypes, and no expectation that medication halts progression.
The pattern that should trigger the thought is repetition with a theme: a 31-year-old with her third left-hemisphere event, infarcts stacked in the deep borderzones, and a CTA report that says "attenuated distal internal carotid arteries bilaterally — correlate clinically." Or the 6-year-old whose arm goes weak whenever he cries hard or blows up a balloon. Both are describing the same physics: a brain living at the edge of its blood supply, run through a network of collaterals doing a job they were never built for.
Angiographically those basal collaterals look like a haze — moyamoya, the Japanese phrase for a puff of smoke drifting in the air, coined by Suzuki when he staged the disease's angiographic march.2
Disease versus syndrome — and why the distinction matters
Moyamoya disease is the idiopathic, typically bilateral form, most prevalent in East Asian populations, with female predominance and a small familial fraction (RNF213 variants in Asian cohorts). Moyamoya syndrome is the same arteriopathy arriving with a known associate — sickle cell disease above all, neurofibromatosis type 1, Down syndrome, prior cranial irradiation.1 The distinction matters practically: the syndrome patient's other disease changes management (transfusion programs in sickle cell, for instance), and unilateral or atypical cases deserve a look for the associate before the "disease" label sticks. Either way, it belongs on the tier-three list of the young-stroke workup and files as "other determined" on the TOAST page.
Two ages, two physiologies
| Children | Adults | |
|---|---|---|
| Dominant presentation | Ischemia: TIAs and infarcts, often borderzone | Ischemia and hemorrhage (rupture of collaterals, often intraventricular or deep) |
| Classic provocation | Crying, hyperventilation, blowing on hot food — hypocapnia constricts the last reserve | Hypotension, dehydration, overtreated blood pressure |
| Other clues | Morning headaches, choreiform movements, cognitive slowing | Recurrent same-territory events with "bilateral distal ICA narrowing" on the report |
| Course | Progression is the rule; earlier revascularization thinking | Progression common; hemorrhagic phenotype drives the JAM question |
Imaging: from "attenuated ICAs" to a Suzuki stage
MRA and CTA raise the diagnosis: bilateral distal ICA / proximal MCA-ACA stenosis with basal collateral networks. FLAIR adds the ivy sign — leptomeningeal high signal from slow pial collateral flow — and diffusion imaging shows the borderzone story. Catheter angiography remains the staging study: Suzuki's six stages track the march from carotid-fork stenosis, through the florid moyamoya haze, to the late stages where the smoke itself vanishes and the hemisphere hangs on external carotid feeders.2 Hemodynamic studies (perfusion imaging with acetazolamide challenge, or equivalents) answer the question the anatomy cannot: how much reserve is left? — which is exactly the number the surgical conversation runs on. Deficits are scored like any stroke (NIHSS); the vessel findings, not the score, drive referral.
"Bilateral distal ICA attenuation" in a young stroke patient is not a curiosity for the follow-up note. It is the sentence that should book the angiogram.
Treatment: flow is the therapy
Revascularization is the intervention that changes the disease's trajectory in symptomatic or hemodynamically failing hemispheres. The direct option — superficial temporal artery to middle cerebral artery (STA-MCA) bypass — restores flow immediately; the indirect options (EDAS and relatives) lay vascularized tissue on the surface and let collaterals grow in over months, the workhorse in children; combined approaches are common in adults.1 For hemorrhagic moyamoya, the randomized JAM trial found direct bypass roughly halved rebleeding and adverse events over five years versus conservative care — the best evidence in the field and the reason adult hemorrhagic presentations deserve a surgical opinion rather than resignation.3
Medical management protects the physiology while the anatomy is addressed — or when surgery is not indicated yet:
- Antiplatelet therapy — commonly a single agent for ischemic phenotypes, on artery-to-artery-embolism logic; evidence is observational, and it is weighed carefully in hemorrhagic presentations. Anticoagulation has no routine role. The general mechanism-first framework is on the antithrombotic selection page — moyamoya is another named exception where it bends.
- Hemodynamic protection — treat dehydration, avoid aggressive blood-pressure lowering, and flag the chart for anesthesia: normocapnia and normotension in the OR, because hyperventilation-induced hypocapnia is a stroke provocation in this disease. In children, even prolonged crying spells matter.
- No expectation that pills halt progression — which is why "watch and re-scan" is itself an active decision with a follow-up date attached, not a discharge.
The bottom line
Moyamoya is what recurrent young stroke looks like when the problem is the head of the carotid itself. Recognize the pattern — same-side, borderzone, provoked by hypocapnia or hypotension, bilateral distal ICA narrowing — stage it with catheter angiography and a hemodynamic study, and route symptomatic disease to a center that does bypass. Protect the physiology in the meantime: full tank, normal CO₂, no heroic blood-pressure lowering. The collaterals are buying time; the surgeon is how you pay it back.
Frequently asked questions.
What is moyamoya disease?
A progressive narrowing of the distal internal carotid arteries and proximal circle of Willis, with fragile basal collateral vessels whose angiographic haze gives the disease its name ("puff of smoke"). It causes recurrent ischemic strokes and TIAs — and, especially in adults, hemorrhage from the overworked collaterals.
What is the difference between moyamoya disease and moyamoya syndrome?
Disease is the idiopathic, usually bilateral form. Syndrome is the same vasculopathy occurring with a recognized associate — sickle cell disease, neurofibromatosis type 1, Down syndrome, or prior cranial radiation. The distinction matters because the associated condition changes management and screening.
Why does hyperventilation or crying provoke symptoms in moyamoya?
Hyperventilation lowers carbon dioxide, which constricts cerebral vessels. A normal brain tolerates this; a moyamoya brain, already running on maximally dilated collaterals with little reserve, cannot — so crying spells, hyperventilation, or blowing hard can transiently drop perfusion below threshold and produce deficits, classically in children.
How is moyamoya treated?
Surgical revascularization — direct STA-MCA bypass, indirect synangiosis, or both — for symptomatic or hemodynamically compromised disease. In adult hemorrhagic moyamoya, the randomized JAM trial showed direct bypass reduced rebleeding versus conservative care. Medical care protects hemodynamics (hydration, no aggressive BP lowering, normocapnia under anesthesia) and commonly uses a single antiplatelet for ischemic phenotypes, but no medication halts progression.
Is a stent an option for moyamoya?
Endovascular angioplasty or stenting of the moyamoya segments has a poor track record — the disease is a progressive wall process, not a focal plaque — and is not a standard therapy. Flow is restored around the disease (bypass), not through it.
References.
- Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome. N Engl J Med. 2009;360(12):1226-1237. PubMed
- Suzuki J, Takaku A. Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol. 1969;20(3):288-299. PubMed
- Miyamoto S, Yoshimoto T, Hashimoto N, et al. Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease: results of the Japan Adult Moyamoya Trial. Stroke. 2014;45(5):1415-1421. PubMed
Related guides
Keep building the picture.
- Stroke in young adults The tiered workup whose third tier books the angiogram.
- TOAST classification Where moyamoya files among the mechanisms: other determined.
- NIHSS calculator Score the deficit like any stroke; the vessels drive the referral.
- Antithrombotic selection The mechanism-first framework moyamoya bends.
Article written by